Ucb logo

Ucb(OTC) UCBJF

Market Cap$45.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+490%
5 Year+121%
1 Year-20%
1 Month-4%
$239.14
-0.46%
-1.10Today
Ucb last closing stock price
MetricPriceDate
Last closeUSD 239.142026-10-16
Ucb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.8%USD 232.632026-10-09
1 month-3.62%USD 248.112026-09-16
3 month-12.48%USD 273.252026-07-17
Year to date-18.04%USD 291.772025-12-31
1 year-20.37%USD 300.302025-10-16
3 year+200.13%USD 79.682023-10-17
5 year+120.92%USD 108.252021-10-15
Since inception+489.6%USD 40.562004-04-20

Ucb Financials at a Glance

Market Cap

$45.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€15.36B

Net Income (TTM)

€3.52B

EPS (TTM)

$13.19

P/E Ratio

17.79

Dividend

$1.70

Beta (Volatility)

-0.04 (Low)

Price

$239.14

Volume

107

Open

$239.14

Previous Close

$239.14

Daily Range

$239.14 - $239.14

52-Week Range

$219.60 - $345.39

Estimated Earnings Date

Feb 25, 2027

UCBJF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ucb

UCB S.A. is a leading biopharmaceutical company focused on developing innovative therapies for neurological and immunological disorders. With a diverse portfolio of marketed products and a robust pipeline, UCB aims to improve the quality of life for patients worldwide.

Products and Services
  • Cimzia for inflammatory TNF-mediated diseases
  • Vimpat, Keppra, and Briviact for epilepsy management
  • Evenity for osteoporosis treatment in postmenopausal women
Growth Outlook
  • Recent quarterly revenue reached €4.26 billion, indicating strong market demand
  • TTM net income of €1.11 billion reflects solid profitability
  • Strategic collaborations with major players enhance growth potential
Financial Highlights
  • TTM P/E ratio of 18.56 suggests reasonable valuation
  • Dividend yield of 0.68% provides steady income for investors
  • Operating income margin of 33.35% demonstrates operational efficiency
UCB S.A. has established itself as a key player in the biopharmaceutical industry, with a commitment to research and development. The company's focus on innovative therapies positions it well for future growth, particularly in the areas of neurology and immunology. Recent financial performance highlights, including strong revenue and net income, underscore the company's operational strength and market presence. With a solid pipeline and strategic partnerships, UCB is poised for continued success in addressing unmet medical needs.
AI Generated • Sep 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,117

CEO

Jean-Christophe Tellier, MD

Website

www.ucb.com

Headquarters

Brussels, BU 1070, BE

UCBJF Financials

Key Financial Metrics (TTM)

Gross Margin

76.23%

Operating Margin

31.23%

Net Income Margin

25.74%

Return on Equity

19.48%

Return on Capital

8.89%

Return on Assets

10.63%

Earnings Yield

5.62%

Dividend Yield

0.71%

Payout Ratio

12.58%

Stock Overview

Market Cap

$45.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

190.66M

Volume

107

Avg. Volume

690.231

Financials (TTM)

Gross Profit

€11.39B

Operating Income

€4.38B

EBITDA

€5.66B

Operating Cash Flow

€3.42B

Capital Expenditure

-€724.58M

Free Cash Flow

€2.70B

Cash & ST Invst.

€795.81M

Total Debt

€3.58B

Ucb Performance Analysis

Ucb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 5,798,225,305-15.1%
20232023-12-31EUR 5,678,019,147-2.1%
20242024-12-31EUR 6,654,561,53317.2%
20252025-12-31EUR 8,736,321,91631.3%
Ucb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3120.4%
Q22025-06-303.7%
Q42025-12-3122.0%
Q22026-06-300.3%
Ucb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 2.25-65.0%
20232023-12-31EUR 1.90-15.7%
20242024-12-31EUR 5.92211.7%
20252025-12-31EUR 9.0652.9%
Ucb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31312.1%
Q22025-06-30-44.7%
Q42025-12-31133.2%
Q22026-06-300.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€4.26B

+52.8%

Gross Profit

€3.18B

+64.0%

Gross Margin

74.64%

N/A

Market Cap

$45.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.51M

N/A

Employees

10,117

N/A

Net Income

€1.11B

+433.3%

EBITDA

€1.73B

+169.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€795.81M

+85.9%

Total Debt

€3.58B

+17.9%

Accounts Receivable

€2.58B

+88.5%

Inventory

€1.74B

+52.9%

Long Term Debt

€3.37B

+12.8%

Short Term Debt

€216.68M

+301.3%

Return on Assets

10.63%

N/A

Return on Invested Capital

16.54%

N/A

Free Cash Flow

€82.88M

-68.2%

Operating Cash Flow

€320.52M

-15.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INCYIncyte Corporation
$113.07-0.18%
REGNRegeneron Pharmaceuticals, Inc.
$790.74-0.70%
VRTXVertex Pharmaceuticals Incorporated
$499.74-1.77%
AZN.LAstraZeneca PLC
£123.54-0.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About UCBJF

What is the current price of Ucb?

Ucb is trading at $239.14 per share.

What is the 52-week range for Ucb?

Over the past 52 weeks, Ucb has traded between $219.60 and $345.39.

How much debt does Ucb have?

As of the most recent reporting period, Ucb reported total debt of €2.64B.

How much cash does Ucb have on hand?

Ucb reported €2.64B in cash and cash equivalents in its most recent financial results.

What is Ucb’s dividend yield?

Ucb currently has a dividend yield of 0.71%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services